GLP-1 Without Insurance: Complete Guide to Paying Out of Pocket (2026)
No insurance? You are not locked out of GLP-1 therapy. Between manufacturer assistance programs, compounded alternatives, oral formulations, and upcoming Medicare expansion, there are more affordable pathways than ever in 2026. This guide covers every option and helps you decide which one fits your budget.
Self-Pay Cost Landscape
The range of GLP-1 costs for uninsured patients spans from $0 to $1,350/month. Your actual cost depends on which programs you qualify for, your risk tolerance regarding compounded products, and whether you prefer injections or pills. Most uninsured patients can find an option under $300/month.
Every Self-Pay Option Compared
Sorted from lowest to highest cost. All prices verified April 2026.
| Option | Monthly Cost | FDA Approved? | Format | Best For |
|---|---|---|---|---|
| Patient Assistance (PAP) | $0 | Yes | Injection | Low-income (<400% FPL) |
| Oral Wegovy (starting) | $149/mo | Yes | Daily pill | Needle-averse, budget-conscious |
| Compounded semaglutide | $149-499 | No (compound) | Injection | Price-sensitive, higher doses |
| $199 Intro Offer | $199/mo | Yes | Injection | New patients, short-term bridge |
| Oral Wegovy (maintenance) | $399-590 | Yes | Daily pill | Long-term oral therapy |
| Ozempic (GoodRx) | $800-950 | Yes | Injection | When no other program applies |
| Wegovy (GoodRx) | $1,100-1,350 | Yes | Injection | Weight-loss specific, no alternatives |
| Mounjaro (GoodRx) | $900-1,100 | Yes | Injection | Tirzepatide preferred |
| Zepbound (GoodRx) | $1,000-1,200 | Yes | Injection | Tirzepatide for weight loss |
Brand Drugs at Cash Price: $900-1,350/Month
Without any savings programs, brand-name GLP-1 medications are among the most expensive chronic therapies in America. These are the pharmacy cash prices you will encounter without intervention.
Ozempic (semaglutide)
$900-1,200/mo
Diabetes indication, commonly prescribed off-label for weight loss
Wegovy (semaglutide)
$1,200-1,350/mo
Weight loss indication, higher max dose
Mounjaro (tirzepatide)
$900-1,100/mo
Diabetes indication, dual GLP-1/GIP mechanism
Zepbound (tirzepatide)
$1,000-1,200/mo
Weight loss indication, highest clinical trial weight loss
Prices reflect typical cash pricing with GoodRx or SingleCare coupons applied. Without any coupon, prices can be $100-200 higher. These cash prices should be your last resort — explore every savings program below first.
Oral Wegovy: The Game Changer for Self-Pay Patients
Oral Wegovy (semaglutide tablets, 50mg daily) is arguably the most significant development for uninsured GLP-1 patients. Approved in late 2025, it offers FDA-approved semaglutide in pill form at a lower price point than injectable Wegovy.
Starting Price
Approximately $149/month for the lowest dose. Maintenance doses (higher strengths) cost more, typically $399-590/month. Still significantly cheaper than injectable Wegovy's $1,350 cash price.
Why It Matters
It is the first FDA-approved oral GLP-1 for weight loss that is price-competitive with compounded injectables. For patients who want the safety assurance of an FDA-approved product without the injectable format, oral Wegovy fills a critical gap.
How to Get It
Available by prescription from your doctor or through telehealth providers. Taken once daily on an empty stomach with a small amount of water. Must wait 30 minutes before eating, drinking, or taking other medications.
Manufacturer Programs for Uninsured Patients
Both Novo Nordisk and Eli Lilly offer programs specifically for patients without insurance coverage. These are the most impactful savings available if you qualify.
Novo Nordisk Patient Assistance Program (PAP)
Provides Ozempic or Wegovy at no cost for U.S. residents with income below 400% FPL (~$62,400 individual) who have no prescription drug coverage. Your prescriber applies on your behalf. Approved for 12 months, renewable annually. This is the single best program for qualifying low-income patients.
Novo Nordisk $199/Month Intro Offer
Available to new patients without coverage. Provides brand-name Ozempic at $199/month for 1-3 months. No income requirement. Designed as a bridge while you pursue longer-term coverage. Enroll at NovoCare.com or call 1-888-693-8276.
Eli Lilly Mounjaro/Zepbound Savings
Eli Lilly has offered similar self-pay programs for Mounjaro and Zepbound, with pricing and terms that vary. Check the Lilly Diabetes Solutions Center (for Mounjaro) or Zepbound.com for current offers. Lilly has historically been competitive with Novo Nordisk on patient access programs.
NeedyMeds & RxAssist
Third-party nonprofit databases that aggregate all available patient assistance programs. If you do not qualify for manufacturer programs directly, these databases may identify alternative funding sources including state programs, disease-specific foundations, and copay assistance charities.
Medicare Coverage Expansion: July 2026
For Americans 65 and older (or those with qualifying disabilities), Medicare Part D will begin covering GLP-1 medications for the obesity indication starting July 2026. This is a watershed moment — previously, Medicare only covered these drugs for type 2 diabetes, leaving millions of seniors paying entirely out of pocket for weight-loss prescriptions.
What to Expect
Specific formulary placement and copays will vary by plan. The Inflation Reduction Act caps total Medicare Part D out-of-pocket costs at $2,000/year, which limits your maximum annual GLP-1 cost regardless of the drug's list price. Prior authorization will likely be required.
How to Prepare
Contact your Part D plan in early summer 2026 to ask about GLP-1 formulary placement. If your current plan does not offer favorable coverage, plan to switch during the Medicare Annual Enrollment Period (October 15 - December 7, 2026) for coverage starting January 2027.
Telehealth Programs That Include Medication
Several telehealth platforms offer all-in-one programs that bundle the prescriber consultation, medication, and ongoing monitoring into a single monthly fee. These can be convenient for self-pay patients who want a simple, predictable cost.
Budget Tier: $149-299/month
Includes lower-dose compounded semaglutide (0.25-1mg) with an initial telehealth consultation and periodic check-ins. Best for patients starting treatment or maintaining on lower doses. Examples: Hims & Hers starting plans, Ro introductory programs.
Mid Tier: $299-499/month
Full-dose compounded semaglutide (1.7-2.4mg equivalent) with monthly provider visits, dosing adjustments, and sometimes metabolic monitoring. Best for patients at maintenance doses who want ongoing clinical oversight. Examples: Henry Meds, Calibrate.
Premium Tier: $400-600/month
Comprehensive weight management programs that include medication plus nutritional counseling, behavioral support, and exercise guidance. Best for patients who want a holistic approach beyond just the medication. Examples: Calibrate Full Program, Found Premium.
Brand-Name Telehealth: $590+/month
Some telehealth platforms now offer brand-name oral Wegovy or facilitate access to branded injectables through their prescribers. Higher cost but with the full safety assurance of FDA-approved products. Best for patients who want the convenience of telehealth with brand-name reliability.
Decision Framework: Which Option Fits Your Budget?
Use this framework to narrow down your options based on your income level and budget.
“I cannot afford any monthly cost”
Apply for the NovoCare Patient Assistance Program. If your household income is below 400% FPL, you can get brand-name Ozempic or Wegovy at no cost. Your prescriber must submit the application.
“I can spend up to $200/month”
Start with the $199/month NovoCare intro offer for brand-name Ozempic (1-3 months). Simultaneously, explore oral Wegovy starting dose at ~$149/month for a longer-term FDA-approved option, or look into compounded semaglutide at $149-249/month for lower doses.
“I can spend $200-500/month”
You have the widest range of options. Consider oral Wegovy at maintenance doses ($399-590), compounded semaglutide at full doses ($299-499), or a telehealth bundle program. At this budget, prioritize FDA-approved options over compounded when possible.
“I can spend $500+/month but want to save”
Consider brand-name injectables with GoodRx/SingleCare coupons ($800-1,100), or a premium telehealth program with brand-name medication. At this budget, there is little reason to use compounded products — the safety advantage of brand-name is worth the premium.
“I am 65+ or approaching Medicare eligibility”
If you are already on Medicare, check your Part D plan for diabetes-indication coverage (Ozempic/Mounjaro). Starting July 2026, obesity coverage expands. Your annual out-of-pocket cap is $2,000. If you are approaching 65, plan your Part D enrollment around GLP-1 coverage.
The Uninsured GLP-1 Patient in 2026: More Options Than Ever
Two years ago, uninsured patients facing GLP-1 costs had essentially two choices: pay $1,000+ per month for brand-name medications, or go without. The market has transformed since then. The compounded semaglutide boom brought prices down to $149-499/month. Manufacturer assistance programs expanded to cover more patients. And most significantly, oral Wegovy's launch created the first FDA-approved option that is price-competitive with compounded alternatives.
The result is that in 2026, most uninsured patients can access GLP-1 therapy for under $300/month if they are willing to do the work of identifying the right program. The challenge is not the absence of affordable options — it is the complexity of navigating them. Each program has its own eligibility requirements, limitations, and trade-offs. The Patient Assistance Program is free but income-restricted. The intro offer is accessible but time-limited. Compounded semaglutide is affordable but carries safety uncertainty. Oral Wegovy is FDA-approved but costs more at maintenance doses.
Looking Ahead: The Affordability Trajectory
The trend is clearly toward greater affordability. Medicare coverage in July 2026 will be the single largest expansion of GLP-1 access. Generic semaglutide could arrive as early as 2031-2032 when key patents expire, potentially dropping costs to $50-100/month. And competition from newer drugs — including oral alternatives and next-generation molecules — is putting pressure on manufacturers to improve pricing. For uninsured patients today, the message is: you have options, they are better than they were a year ago, and they will continue improving.
Frequently Asked Questions
What is the cheapest GLP-1 medication without insurance?
The cheapest FDA-approved option is oral Wegovy at approximately $149/month for the starting dose (manufacturers have indicated introductory pricing in this range). The cheapest overall option is compounded semaglutide at $149-249/month for lower doses, though it is not FDA-approved as a finished product and carries additional safety risks. If you qualify for the NovoCare Patient Assistance Program, brand-name Ozempic or Wegovy is available at no cost.
Can I get Ozempic for free without insurance?
Yes, through Novo Nordisk's Patient Assistance Program (PAP). You must be a U.S. resident with household income below 400% of the Federal Poverty Level (approximately $62,400 for an individual in 2026) and have no prescription drug coverage. Your prescriber must complete the application. If approved, Ozempic is provided at no cost for 12 months, renewable annually.
Is it worth paying out of pocket for a GLP-1?
That depends on your financial situation and health needs. For patients with obesity-related comorbidities (type 2 diabetes, sleep apnea, cardiovascular risk), GLP-1 medications can reduce healthcare costs long-term by preventing expensive complications. For weight loss alone, weigh the monthly cost against the clinical benefit and your budget. Many patients find that the health improvements justify the expense, but it is a personal financial decision.
Are telehealth GLP-1 programs legitimate?
Many are legitimate, but quality varies enormously. Established platforms like Hims & Hers, Ro, and Calibrate use licensed prescribers and partner with registered pharmacies. However, some smaller operations cut corners on medical oversight. Red flags include: no medical questionnaire or consultation, guaranteed approval without evaluation, unusually low prices, and inability to identify their compounding pharmacy. Always verify the provider's medical licenses and pharmacy partnerships.
Will Medicare cover GLP-1s for weight loss in 2026?
Yes, starting July 2026 Medicare will cover GLP-1 medications for the obesity indication under expanded provisions. Specific formulary placement, copay amounts, and prior authorization requirements will vary by Medicare Part D plan. The Inflation Reduction Act caps total Medicare Part D out-of-pocket costs at $2,000/year across all medications, which limits GLP-1 cost exposure. Contact your Medicare plan for specific details as coverage begins.
Can I buy Ozempic from Canada or overseas?
Importing prescription drugs from other countries is technically illegal under federal law, though the FDA has historically exercised enforcement discretion for personal-use quantities. Ozempic costs roughly $150/month in Canada and even less in other countries. However, buying overseas carries risks: counterfeit medications are prevalent in unregulated channels, you may not get the correct product, and there is no recourse if something goes wrong. We recommend exploring domestic savings programs first.
How do I decide between compounded semaglutide and oral Wegovy?
Oral Wegovy is FDA-approved, manufactured by Novo Nordisk under strict quality controls, and has clinical trial data supporting its efficacy. Compounded semaglutide is cheaper but not FDA-approved as a finished product and carries documented safety risks. If the price difference is small ($149 for oral Wegovy starting dose vs $149-249 for compounded), oral Wegovy is the clear better choice. If you need higher doses and the cost gap is significant, the decision involves weighing price against safety assurance.
Find Your Best Price
Our cost comparison tool factors in your insurance status, income, and preferences to find the cheapest legitimate GLP-1 option for your situation.
Disclaimer: Pricing information is for educational purposes and may not reflect current availability. Program terms, eligibility, and prices change frequently. Always verify current details directly with the provider or manufacturer. Compounded medications are not FDA-approved finished products and carry additional risks. Consult your prescriber before starting any GLP-1 medication. GLP-1 Watchdog is not affiliated with any pharmaceutical company, telehealth provider, or compounding pharmacy.